A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Target Recruit Count
- 99
- Registration Number
- NCT06143735
- Locations
- 🇨🇳
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
🇨🇳Shandong Cancer Hospital & Institute, Jinan, Shandong, China
🇨🇳Sichuan Cancer Hospital, Chengdu, Sichuan, China
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- Drug: TQB2450 +Anlotinib+DocetaxelDrug: TQB2450 +Androtinib Placebo+Docetaxel
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Target Recruit Count
- 148
- Registration Number
- NCT06141226
- Locations
- 🇨🇳
The Central People's Hospital of Huizhou, Huizhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, China
🇨🇳The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu, China
Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma
- Conditions
- Gastric Neuroendocrine Carcinoma
- Interventions
- Drug: Sintilimab，Surufatinib
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Target Recruit Count
- 20
- Registration Number
- NCT06102746
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed
- Conditions
- Gastric Cancer
- Interventions
- Drug: Adebrelimab，Fruquintinib
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Target Recruit Count
- 30
- Registration Number
- NCT06102759
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Drug: Adebrelimab，Fruquintinib
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Target Recruit Count
- 30
- Registration Number
- NCT06102772
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Drug: Fruquintinib, TAS102
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Target Recruit Count
- 30
- Registration Number
- NCT06102785
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
- Conditions
- Cervical CancerInduction ChemotherapyImmunotherapy
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 20
- Registration Number
- NCT06093438
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
- Conditions
- Esophageal Cancer
- Interventions
- Radiation: Arm ARadiation: Arm B
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-12-26
- Target Recruit Count
- 136
- Registration Number
- NCT06061146
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer
- Conditions
- Gastric CancerNo.12a Lymph Node Dissection
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Target Recruit Count
- 100
- Registration Number
- NCT06033482
- Locations
- 🇨🇳
Department of Gastric cancer, Tianjin Medical University Cancer Institute & Hospital,, Tianjin, None Selected, China
A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery
- Conditions
- Gastric CancerPredictive Cancer ModelHepatic Metastasis
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2023-10-26
- Target Recruit Count
- 120
- Registration Number
- NCT06023966
- Locations
- 🇨🇳
Cancer Hospital of Tianjin Medical University, Tianjin, 天津, China